Business
Apollo Capital Comments on MediPharm Labs' Failure to Respond to Reasonable Offer to Ensure Fair, Lawful and Transparent 2025 Annual Meeting
MediPharm Labs Board Continues to Obstruct the Appointment and Oversight of an Independent Chair ...
About this update from Medipharm Labs Corp.
[{"type":"text","content":"Apollo Capital Comments on MediPharm Labs’ Failure to Respond to Reasonable Offer to Ensure Fair, Lawful and Transparent 2025 Annual Meeting\n\n\n\n\n MediPharm Labs Board Continues to Obstruct the Appointment and Oversight of an Independent Chair\n \n\n\n\n Failure to Appoint an Independent Chair to Oversee the Election of Directors at the Annual Meeting Prevents Shareholders from Exercising their Legal Right to Hold the Current Board Accountable for their Epic Failures\n \n\n\n\n Board Made No Attempt to Engage with Apollo Capital; Instead Resorted to Continued Campaign of Misdirection and Character Assassination Aimed to Undermine Shareholders Demanding Change\n \n\n\n\n Shareholders Deserve the Opportunity to Elect New Leaders in a Lawful and Fair Election\n \n\n\n\n Apollo Capital Reiterates Commitment to Transparent Election Process for the Benefit of All Shareholders\n \n\n\n\n URGES SHAREHOLDERS TO DISREGARD MEDIPHARM LABS’ GREEN PROXY CARD AND VOTE THE\n \n\n\n\n GOLD\n \n\n\n\n PROXY CARD \"FOR\" APOLLO CAPITAL'S SIX DIRECTOR NOMINEES\n \n\n\n TORONTO, May 23, 2025 (GLOBE NEWSWIRE) -- Apollo Technology Capital Corporation (“Apollo Capital”) which together with its affiliates and associates collectively is one of the largest shareholders of MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm Labs”, or the “Company”), owning approximately 3% of the Company’s common stock, today announced that MediPharm Labs’ Board of Directors (the “Board”) did not respond to Apollo Capital’s “With Prejudice” offer to the Board to ensure the rights of shareholders are protected in connection with the Company’s upcoming 2025 Annual and Special Meeting of Shareholder to be held on June 16, 2025 (the “Annual Meeting”).\n \n\n Apollo Capital distributed the offer to MediPharm Labs counsel on May 21, 2025 – seeking to ensure a lawful and fair election overseen by an independent Chair in order to protect the rights of shareholders at the Annual Meeting. The offer, which Apollo Capital shared publicly, was unilaterally ignored by MediPharm Labs’ Board, who made no attempts whatsoever to engage with representatives of Apollo Capital.\n \n\n Apollo Capital Chairman and CEO Regan McGee comme...